Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01319903
Other study ID # IFX-1-P1.1
Secondary ID 2010-023647-15
Status Completed
Phase Phase 1
First received March 18, 2011
Last updated January 12, 2012
Start date March 2011
Est. completion date October 2011

Study information

Verified date January 2012
Source InflaRx GmbH
Contact n/a
Is FDA regulated No
Health authority Germany: Paul-Ehrlich-Institut
Study type Interventional

Clinical Trial Summary

The novel humanized monoclonal antibody CaCP29 was developed to control the inflammatory response to various stimuli in humans and espacially during sepsis. Purpose of this phase I clinical trial in healthy human males is to investigate various parameters concerning safety and tolerability of CaCP29 and assess pharmacokinetic and pharmacodynamic parameters.


Description:

The acute inflammatory innate host response, as being present during the development of sepsis and various other acute inflammatory diseases, represents a powerful mechanisms which can lead to destruction of host tissue and severe organ dysfunction. CaCP29 was developed to lower the complement mediated acute inflammatory response and thereby control the extend of a strongly activated often times self-destructive inflammatory response by controlling activation of a key inflammatory mechanism.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date October 2011
Est. primary completion date October 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- Male, Caucasian subjects aged between 18-40 years (inclusive)

- Healthy subjects as determined by medical history, physical examination

- Body weight between 70 - 100 kg and BMI between 19 and 29 kg/m2, extremes incl

- ECG recording based on a 12-lead ECG which is normal (PR < 210 ms, QRS <110 ms, QTC 380 -430 ms) or contains only slight deviations

- Normal vital signs (after 5 minutes resting), blood pressure values (systolic > or equal to 100 and < or equal to 140 mmHg, diastolic > or equal to 50 and < or equal to 90 mmHg), heart rate between 45 and 90 beats per minute (bpm), body temperature < 37.5°C

- Subjects who are able and willing to give written informed consent

- Normal white blood cell count, CRP and IL-6 at screening and Day -1

- Subjects must be using two acceptable methods for contraception (e.g. spermicide and condom) during the study and refrain from fathering a child in the 3 months following dosing

Exclusion Criteria:

- In the opinion of the investigator subjects with clinically significant history or presence of cardiovascular, respiratory, renal, hepatic, metabolic, endocrinological, gastrointestinal, hematological, neurological, dermatological, psychiatric diseases, cancer or other major diseases;

- Infection or known inflammatory process;

- Known autoimmune diseases or immunodeficiency or known family history of autoimmune diseases or immunodeficiency;

- Clinical significant allergic disease;

- Known serum hepatitis or who are carriers of the Hepatitis B surface antigen or Hepatitis C antibodies or with a positive result to the test for HIV 1/2 antibodies;

- Subjects who have received an investigational drug and/or a vaccination within 3 months prior to start of the treatment in study and those who anticipate receipt of a vaccine within 2 months after the last dose of study drug;

- Subjects, who have received prior treatment within 1 year with monoclonal antibodies or other biologic agents;

- The use of any concomitant prescription or non-prescription medication within 14 days prior to the first administration of study medication until follow-up; or treatment with medication that may affect immune function (e.g. immunoglobulins, corticosteroids) within 6 months before dosing;

- Donation of blood (>400 ml) or blood products within the last 3 months prior to admission to the clinical unit or plasmapheresis within 4 weeks prior to study start;

- Definite or suspected personal history of adverse reactions or hypersensitivity to drugs especially to the ingredients of the trial compound or to compounds with a similar structure;

- Use of more than 5 cups or glasses of coffee, tea and / or cola per day;

- Presence or history of drug and/or alcohol abuse or an average daily intake of more than 20 g alcohol per day;

- Positive test for alcohol or drugs at screening and/or on Day -1;

- Smokers of > 5 cigarettes/day or equivalent;

- Subjects who are unlikely to be compliant and attend scheduled clinic visits as required;

- Participation in this study on a previous dose level

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
CaCP29, a humanized monoclonal antibody
CaCP29 or placebo single i.v. infusion in ascending doses in healthy human males

Locations

Country Name City State
Germany FOCUS Clinical Drug Development GmbH Neuss Nordrhein-Westfalen

Sponsors (1)

Lead Sponsor Collaborator
InflaRx GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number and extent of changes in safety relevant parameters after injection of CaCP29 Safety relevant parameters include changes from baseline of:
cytokine levels over time (IL-6, IL-8, IFN-gamma, TNF-alpha, IL-10)
CH50 activity over time
standard hematology, clinical chemistry and coagulation laboratory parameters
12-lead ECG
vital signs
pre-dose, days 1,2,3,7,14,28 and 70 Yes
Secondary Assessment of pharmacokinetic parameters of CaCP29 over time Area under the plasma concentration versus time curve (AUC) of CaCP29
Peak Plasma Concentration (Cmax) of CaCP29 and time to reach Cmax
terminal phase half-life
clearance
volume of distribution during the terminal phase
pre-dose, day 1,2,3,7, 14, 28 and 70 No
Secondary Number of Participants developing anti-CaCP29 antibodies - Immunogenicity pre-dose, days 28 and 70 No
Secondary Bioactivity of CaCP29 in human whole blood over time after injection pre-dose, days 1,2,3,7,14,28 and 70 No
See also
  Status Clinical Trial Phase
Completed NCT01425502 - Data-driven Quality Improvement in Primary Care - Trial N/A
Recruiting NCT01756183 - Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer Phase 2
Completed NCT01355016 - A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers Phase 1
Completed NCT01757860 - Safety and Pharmacokinetics Study of CARD-024 in Healthy Subjects Phase 1
Completed NCT01179854 - Remegal Different Doses in Patients With Refractory Partial Seizures Phase 2
Completed NCT00376415 - A Safety Study of Lessertia Frutescens in Adults. Phase 1
Active, not recruiting NCT01722916 - Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase Early Phase 1
Completed NCT01727778 - Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT01475097 - Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography Phase 4
Completed NCT01412658 - Clinical Safety of a Novel Milk Protein Peptide Phase 1
Terminated NCT01847222 - An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers. Phase 1
Unknown status NCT01633099 - Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients Phase 3
Recruiting NCT01297842 - Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections Phase 4
Completed NCT01284582 - Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP) Phase 1
Completed NCT01556607 - A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Subjects With Intermittent, or Mild-to-Moderate Persistent, Asthma Phase 1
Completed NCT01557270 - Efficacy and Safety Study of Dexmedetomidine as an Additive to Local Anesthetics in Shoulder Surgery Phase 3
Completed NCT01271569 - A Study to Assess the Efficacy and Safety of Fospropofol Disodium Phase 1
Recruiting NCT04785027 - Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis Phase 1/Phase 2
Completed NCT01428882 - Propofol vs. Midazolam-based Balanced Propofol for Nonanesthesiologist Moderate Sedation in Colonoscopy Phase 4
Completed NCT01367873 - Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects Phase 1